Abstract:319 Background: Esophageal squamous cell carcinoma (ESCC) is a kind of cancer with high incidence and high mortality in China, and there is no effective treatment at present. Camrelizumab as a single agent has shown a higher survival benefit in clinical studies of second-line treatment of ESCC, but the degree of tumor remission is limited. Therefore, anti-angiogenic drugs and low-dose chemotherapeutics were added to observe and evaluate the efficacy and safety of Camrelizumab combined with Apatinib and Irinotecan in the second-line treatment of advanced ESCC. Methods: This is a single-arm, multi-center, phase II study. Patients over 18 years old, male or female, with ECOG score of 0-2, who had received systemic first-line chemotherapy (including concurrent chemoradiotherapy for distant metastases within 6 months), and who were diagnosed as ESCC by histopathology or cytology were included in the study, there were no severe hematopoietic dysfunction, heart, lung, liver, kidney dysfunction and immune deficiency. Results: As of June 29, a total of 42 patients were enrolled, of which 16 patients can be evaluated for efficacy.Among the 16 patients, 5 were out of the group due to progress, intolerance and active withdrawal, while the rest were still in the process of clinical research. The baseline characteristics of 16 patients were as follows: most of the patients were male (75%) and the ECOG score was poor (ECOG 1-2, 93.75%). All the patients were ESCC, and the degree of tissue differentiation was moderate to low differentiation, moderate differentiation (50%), and the location of cancer was middle thoracic (37.5%); Most of the patients had not received radiotherapy (75.0%) or targeted drug therapy (87.5%); Most of the first-line chemotherapy regimens were paclitaxel plus platinum (85%), and 12.5% of the patients used fluorouracil plus platinum. Among the 16 patients, the best efficacy evaluation distribution was: 1 patient with CR, 8 patients with PR, 4 patients with SD, 2 patients with PD, ORR was 56.25%, DCR was 81.25%; the median PFS and OS were not reached. In terms of safety, the incidence of adverse reactions at any level is 75%, of which the most common adverse reactions are fatigue (50%), gastrointestinal reactions (25%) and hypertension (18.8%); adverse reactions above grade 3 are fever (12.5%), no new safety signals appeared. Conclusions: This is the first study to explore PD-1 inhibitors combined with anti-angiogenesis inhibitors and DNA topoisomerase I inhibitors as second-line treatments for advanced ESCC. Camrelizumab combined with Apatinib and Irinotecan as a second-line treatment has shown encouraging clinical efficacy and acceptable safety, and may be a favorable option for patients with advanced ESCC. A further phase III randomized trial is needed. Clinical trial information: ChiCTR2000028857.

Clinical observation of cyclophosphamide combined with hydroxycamptothecin as second-line treatment on advanced Ewing's sarcoma

Cyclophosphamide-Hydroxycamptothecin As Second-Line Chemotherapy for Advanced Ewing'S Sarcoma: Experience of A Single Institution

Efficacy of second-line chemotherapy for advanced osteosarcoma

Clinical Observation of Gemcitabine Combined with Docetaxel in the Treatment of Ad-Vanced Recurrent and Metastatic Osteosarcoma

Efficacy of high dose chemotherapy in adult patients with relapsed or refractory ewing sarcoma

Anti-PD1/PDL1 Antibodies Plus Chemotherapy As First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

Clinical study on the second-line treatment of advanced esophageal squamous cell carcinoma with camrelizumab combined with apatinib and irinotecan: A single-arm, multicenter, phase II study.

Eribulin and Irinotecan for Refractory or Recurrent Ewing Sarcoma: A Retrospective Study.

Clinical observation of continuous-infusion with high-dose ifosfamide plus adriamycin on advanced soft tissue sarcomas

[Clinical Report on Diagnosis and Treatment of 14 Cases with Pediatric Ewing's Sarcoma Family Tumors].

Efficacy and safety of anthracycline combined with alkylating agent for treatment of advanced leiomyosarcoma.

Management of Recurrent or Refractory Ewing Sarcoma: A Systematic Review of Phaseii Clinical Trials in the Last 15Years

Advances in Chemotherapy and Radiotherapy Combined with Molecular Targeted Therapy for Ewing's Sarcoma

Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma

Continuous-infusion Ifosfamide and Doxorubicin Combination As Second-Line Chemotherapy for Recurrent or Refractory Osteosarcoma Patients in China: a Retrospective Study

Phase 1 study of cabozantinib in combination with topotecan–cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma

Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies

Real World Effectiveness of Immunotherapy Combined with Anti-Angiogenic Therapy in Patients with Anthracycline-Resistant Soft Tissue Sarcomas.

Effective combination of cold physical plasma and chemotherapy against Ewing sarcoma cells in vitro

The Open, Multicenters, Double-Arms, Randomized, Parallel Controlled Clinical Trial of Lobaplatin or Gemcitabine Combined with Docetaxel As Second-Line Therapy for Advanced Osteosarcoma-the Effectiveness and Safety Analysis.

Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature